Clinical trial
RAD001 Plus Best Supportive Care (BSC) Versus BSC Plus Placebo in Patients With…
NCT00410124 · Novartis Pharmaceuticals, Industry · Completed
Key facts
| NCT number | NCT00410124 |
|---|---|
| Title | RAD001 Plus Best Supportive Care (BSC) Versus BSC Plus Placebo in Patients With Metastatic Carcinoma of the Kidney Which Has Progressed After Treatment With Sorafenib and/or Sunitinib |
| Official title | A Randomized, Double-blind, Placebo-controlled, Multicenter Phase III Study to Compare the Safety and Efficacy of RAD001 Plus Best Supportive Care (BSC) Versus BSC Plus Placebo in Patients With Metastatic Carcinoma of the Kidney Which Has Progressed on VEGF Receptor Tyrosine Kinase Inhibitor |
| Acronym | RECORD-1 |
| Lead sponsor | Novartis Pharmaceuticals, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Metastatic Renal Cell Carcinoma |
| Intervention type | Drug |
| Interventions | RAD001, Placebo |
| Enrollment | 416 |
| Start date | Nov 1, 2006 |
| Primary completion | Feb 1, 2008 |
| Completion | Oct 1, 2011 |
| First posted | Dec 12, 2006 |
| Last update posted | Jan 15, 2013 |
| Countries | Australia, Canada, France, Germany, Italy, Japan, Netherlands, Poland, Spain, United States |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: